The identified compounds (Dexverapamil, Emetine, Parthenolide, Dobutamine, Terfenadine, Pimozide, Mefloquine, Ellipticine, and Trifluoperazine) present promising mechanisms of action involving modulation of HERG, adrenergic receptor Alpha-1a, dopamine D3 receptor, epidermal growth factor receptor erbB1, C-C chemokine receptor type 5, muscarinic acetylcholine receptors, glycine receptor subunit alpha-1 and others, which could potentially enhance PCa treatment. Here, DRD3 is linked to posterior cortical atrophy.